Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Rallybio Corporation Market Cap
From what 0 stock analysts predict, the share price for Rallybio Corporation (RLYB) might increase by 854.55% in the next year. This is based on a 12-month average estimation for RLYB. Price targets go from $6 to $15. The majority of stock analysts believe RLYB is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assigned RLYB 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Rallybio Corporation to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on RLYB. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of RLYB.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Mitchell Kapoor HC Wainwright & Co. | Buy | $6 | Reiterates | Sep 3, 2024 |
| Josh Schimmer Evercore ISI Group | Outperform | $15 | Maintains | Aug 26, 2024 |
| Mitchell Kapoor HC Wainwright & Co. | Buy | $6 | Maintains | Aug 12, 2024 |
| Anupam Rama JP Morgan | Neutral | Downgrade | May 15, 2024 | |
| Mitchell Kapoor HC Wainwright & Co. | Buy | $9 | Reiterates | May 10, 2024 |
| Jonathan Wolleben JMP Securities | Market Outperform | $8 | Reiterates | Apr 19, 2024 |
| Jonathan Wolleben JMP Securities | Market Outperform | $8 | Reiterates | Apr 18, 2024 |
| Laura Chico Wedbush | Outperform | $11 | Maintains | Apr 11, 2024 |
| Jonathan Wolleben JMP Securities | Market Outperform | $8 | Reiterates | Mar 13, 2024 |
| Mitchell Kapoor HC Wainwright & Co. | Buy | $9 | Maintains | Mar 13, 2024 |
| Mitchell Kapoor HC Wainwright & Co. | Buy | $12 | Maintains | Feb 7, 2024 |
| Eun Yang Jefferies | Hold | $1.5 | Downgrade | Feb 7, 2024 |
| Laura Chico Wedbush | Outperform | $13 | Maintains | Feb 7, 2024 |
| Jonathan Wolleben JMP Securities | Market Outperform | $8 | Maintains | Feb 7, 2024 |
| Josh Schimmer Evercore ISI Group | Outperform | $15 | Maintains | Dec 21, 2023 |
| Mitchell Kapoor HC Wainwright & Co. | Buy | $17 | Reiterates | Nov 29, 2023 |
| Laura Chico Wedbush | Outperform | $14 | Maintains | Nov 10, 2023 |
| Mitchell Kapoor HC Wainwright & Co. | Buy | $17 | Maintains | Nov 10, 2023 |
| Mitchell Kapoor HC Wainwright & Co. | Buy | $18 | Reiterates | Sep 5, 2023 |
| Jonathan Wolleben JMP Securities | Market Outperform | $16 | Reiterates | Sep 5, 2023 |
When did it IPO
2021
Staff Count
25
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Stephen Uden M.B, M.D.
Market Cap
$45.6M
In 2023, RLYB generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that RLYB's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 02 Nov 2023
Sentiment - NEUTRAL
Source - Business Wire
Summary - NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced that an abstract for the Rallybio Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) natural history study has been accepted for poster presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting, which will be held December 9-12, 2023, in San Diego, California. Details of the poster presentation are as follows: Title: Identifying Pregnancies at Higher Risk for HPA-1a Alloimmuniz.
Tue, 03 Oct 2023
Sentiment - NEUTRAL
Source - Business Wire
Summary - NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Stephen Uden, M.D., Chief Executive Officer of Rallybio, will participate in a panel discussion, u201cNovel Platform Technologies in Rare Disease and Oncology,u201d at the JonesTrading 2023 Healthcare Summit on October 10, 2023 at 11:00 a.m.
Fri, 15 Sep 2023
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Rallybio has proof of concept data from two more assets, RLYB211 and RLYB116, in addition to their lead asset RLYB212. RLYB212 demonstrated rapid and complete elimination of transfused platelets in patients, while RLYB116 showed a reduction in Free C5 greater than 99%. The company has a cash balance of $138mn and a cash runway of approximately 6 quarters.
Sun, 03 Sep 2023
Sentiment - NEUTRAL
Source - Business Wire
Summary - NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today presented clinical data in a poster from the Phase 1 first-in-human single ascending dose (SAD) clinical study in healthy participants of RLYB116. RLYB116 is an innovative potentially long-acting, subcutaneously injected inhibitor of C5 in developme.
Thu, 31 Aug 2023
Sentiment - NEUTRAL
Source - Business Wire
Summary - NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences: 2023 Wells Fargo Healthcare Conference in Everett, MA on Thursday, September 7, 2023. Stephen Uden, M.D., Chief Executive Officer, and Martin Mackay, Ph.D., Executive Chairm.
Tue, 08 Aug 2023
Sentiment - NEUTRAL
Source - Business Wire
Summary - NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today reported financial results for the second quarter ended June 30, 2023 and provided an update on recent program and corporate developments. u201cWe continue to make significant progress across our portfolio. We were pleased to have results from the Phase 1b proof-of-concept study for RLYB212, our anti-HPA-1a monoclonal antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), presented at the In.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
